Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: a new tracer for cancer detection.
18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and 18F-2-fluoro-2-deoxy-D-mannose (18F-FDM) were tested as tumor diagnostic agents in a transplantable rat tumor and rabbit tumors. Tissue distribution studies in rats showed high tumor uptakes of both radiopharmaceuticals. The tumor uptake reached 2.65 +/- 0.61% dose 18 dose F-FDG/g and 2.65 +/- 0.81% dose 18F-FDM/g at 60 min and remained relatively constant until 120 min. Blood clearance both 18F-FDG and 18F-FDM was very rapid and tumor-to-blood ratios reached 22.1 and 29.4 at 60 min, respectively. Tumor-to-tissue ratios of both radiopharmaceuticals were very high in most organs, especially in the liver, kidney, and pancreas. Positron emission tomography (PET) of rabbit tumor with 18F-FDM clearly delineated the main tumor, central necrosis, and lymph node metastases. These data suggested that 18F-FDM, which is a by-product of 18F-FDG synthesis was also an excellent cancer diagnostic agent as well as 18F-FDG. This is not only a new feature of 18F-FDM, but also an economical improvement on cancer diagnosis by PET.
D000818:Animals; D001345:Autoradiography; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging*; D003837:Deoxy Sugars; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005461:Fluorine; D019788:Fluorodeoxyglucose F18; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging*; D008297:Male; D009368:Neoplasm Transplantation; D011817:Rabbits; D011868:Radioisotopes; D051381:Rats; D012210:Rhamnose / Q000031:analogs & derivatives*; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
D003837:Deoxy Sugars; D011868:Radioisotopes; D019788:Fluorodeoxyglucose F18; D005461:Fluorine; C017190:2-deoxy-2-fluoromannose; D003847:Deoxyglucose; D012210:Rhamnose